Name: VYNE Therapeutics Inc. (VYNE) Financial Statements
Creator: FinSpry

VYNE Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

VYNE Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.50	0.42	0.48	0.93	20.99
Cost of Revenue	0.00	0.00	0.00	3.35	1.39
Gross Profit	0.50	0.40	0.48	0.93	19.60
Operating Expenses
Research & Development	30.95	16.31	18.39	19.54	43.53
Selling, General & Administrative	13.19	13.38	16.39	20.30	89.54
Operating Expenses	44.14	29.68	34.77	39.84	133.08
Operating Income	-43.64	-29.26	-34.30	-38.91	-113.48
Other Income/Expense
Interest Income	0.00	1.39	0.36	0.00	0.00
Interest Expense	0.00	0.00	0.00	-5.61	-4.39
Other Income/Expense	3.83	1.39	0.36	-0.14	0.97
Income
Income Before Tax	-39.80	-27.87	-33.93	-44.66	-255.83
Income Tax Expense	0.00	-0.12	0.01	-0.45	-0.26
Net Income	-39.83	-28.45	-23.21	-73.33	-255.57
Net Income - Continuous Operations	-39.83	-27.87	-33.95	-44.21	0.00
Net Income - Discontinued Operations	-0.03	-0.58	10.74	-29.12	0.00
EBITDA	-43.63	-29.26	-34.22	-38.80	-113.13
EBIT	-39.77	-29.26	-34.30	-38.91	-113.48
Depreciation & Amortization	0.00	0.07	0.07	0.11	0.34
Earnings Per Share
Basic EPS	-1.00	-3.00	-7.00	-26.00	-142.00
Diluted EPS	-1.00	-3.00	-7.00	-26.00	-142.00
Basic Shares Outstanding	42.59	10.27	3.19	2.86	1.80
Diluted Shares Outstanding	42.59	10.27	3.19	2.86	1.80